Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Synthetic lethality as a basis to select drug combinations

Prof René Bernards - Netherlands Cancer Institute, Amsterdam, Holland

Synthetic lethality as a basis to select drug combinations ( Prof René Bernards - Netherlands Cancer Institute, Amsterdam, Holland )

Genomic analysis of childhood tumours; biological and therapeutic implications

Dr Peter Lichter - German Cancer Research Center (DKFZ), Heidelberg, Germany

Genomic analysis of childhood tumours; biological and therapeutic implications ( Dr Peter Lichter - German Cancer Research Center (DKFZ), Heidelberg, Germany )

Proteogenomics in cancer research

Dr Henry Rodriguez - National Cancer Institute (NIH), Bethesda, USA

Proteogenomics in cancer research ( Dr Henry Rodriguez - National Cancer Institute (NIH), Bethesda, USA )

Novel models to personalise cancer therapeutics

Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden

Novel models to personalise cancer therapeutics ( Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden )

Latest in relapsed and refractory multiple myeloma

Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim

$Latest in relapsed and refractory multiple myeloma ( Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim )$

Lenalidomide with CD19 antibodies in L-MIND

Dr Kami Maddocks - Ohio State University, Columbus, USA

Lenalidomide with CD19 antibodies in L-MIND ( Dr Kami Maddocks - Ohio State University, Columbus, USA )

Denosumab or zoledronic acid for bone disease in multiple myeloma

Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece

Denosumab or zoledronic acid for bone disease in multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )

Extended followup indicates daratumumab with bortezomib and dexamethasone for...

Prof Katja Weisel - University of Tübingen, Tübingen, Germany

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )

Triplet therapy for all comers in the CLL-BAG trial

Dr Paula Cramer – University of Cologne, Cologne, Germany

Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA

Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France

Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany

400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )

More from ecancer